{"filing":{"accession_number":"0001104659-26-091280","cik":"0001581280","ticker":"TWST","company_name":"Twist Bioscience Corp","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-04","primary_document":"tm2622018d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581280/000110465926091280/tm2622018d2_8k.htm"},"events":[{"id":24239,"run_id":21947,"accession_number":"0001104659-26-091280","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Twist Bioscience completed a registered public offering of 3,125,000 shares of common stock at $96.00 per share, with underwriters exercising their option to purchase an additional 468,750 shares, generating approximately $327.1 million in net proceeds. The offering was upsized from an initially proposed $250.0 million and will dilute existing shareholders while providing capital for R\u0026D, manufacturing expansion, and general corporate purposes.","company_name":"Twist Bioscience Corp","ticker":"TWST","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24725,"accession_number":"0001104659-26-091280","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Twist Bioscience entered into an underwriting agreement on August 4, 2026, to issue and sell 3,125,000 shares of common stock at $96.00 per share, with underwriters exercising their option to purchase an additional 468,750 shares on August 5, 2026. The offering is expected to generate approximately $327.1 million in net proceeds. This is a registered public offering of equity securities that will dilute existing shareholders and is material to investors assessing the company's capital structure and ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:40:30.196420+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24726,"accession_number":"0001104659-26-091280","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Twist Bioscience announced a registered public offering of 3,125,000 shares of common stock at $96.00 per share for $300.0 million in gross proceeds (upsized from an initially proposed $250.0 million offering). This is a material dilutive equity issuance disclosed via Item 7.01 (Regulation FD Disclosure) with two press releases documenting the announcement and pricing. The offering directly dilutes existing shareholders and raises capital for R\u0026D, manufacturing expansion, and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:40:30.196420+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24725,"accession_number":"0001104659-26-091280","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Twist Bioscience entered into an underwriting agreement on August 4, 2026, to issue and sell 3,125,000 shares of common stock at $96.00 per share, with underwriters exercising their option to purchase an additional 468,750 shares on August 5, 2026. The offering is expected to generate approximately $327.1 million in net proceeds. This is a registered public offering of equity securities that will dilute existing shareholders and is material to investors assessing the company's capital structure and ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:40:30.196420+00:00","company_name":"Twist Bioscience Corp","ticker":"TWST","filing_date":"2026-08-05"},{"id":24726,"accession_number":"0001104659-26-091280","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Twist Bioscience announced a registered public offering of 3,125,000 shares of common stock at $96.00 per share for $300.0 million in gross proceeds (upsized from an initially proposed $250.0 million offering). This is a material dilutive equity issuance disclosed via Item 7.01 (Regulation FD Disclosure) with two press releases documenting the announcement and pricing. The offering directly dilutes existing shareholders and raises capital for R\u0026D, manufacturing expansion, and general corporate purposes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:40:30.196420+00:00","company_name":"Twist Bioscience Corp","ticker":"TWST","filing_date":"2026-08-05"}]}